MedTrace Logo

Bacteriophage Therapy in Patients With Urinary Tract Infections

NCT04287478 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-03-03

No results posted yet for this study

Summary

This is a phase I/II trial designed to evaluate bacteriophage therapy in patients with urinary tract infections.

Conditions

  • Urinary Tract Infection Bacterial

Interventions

BIOLOGICAL

Bacteriophage Therapy

Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Adaptive Phage Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert J Hopkins, MD · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2023-02-28
Completion
2023-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287478 on ClinicalTrials.gov